Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vivo Capital
Palo Alto, California, United Statesvivocapital.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Vivo Capital manages over $5.3 billion in assets and has invested in more than 430 public and private healthcare/life sciences companies globally since its founding in 1996. Its funds have supported the development of multiple FDA-approved therapies via investments in biotechs such as Verona Pharma ("Ohtuvayre" for COPD), Geron Corporation ("Rytelo" for myelodysplastic syndrome), Avadel Pharmaceuticals ("Lumryz" for narcolepsy), Soleno Therapeutics ("Vykat XR" for Prader-Willi Syndrome) among others. Several portfolio companies have been acquired by major pharmaceutical firms following clinical or commercial success.
- Therapeutic areas
- Other
- Modalities
- not applicable — invests across all modalities
- Industry
- Investors
02
Partnerships
Global institutional LP base/co-investors
Beyond the preview
Go deeper on Vivo Capital.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vivo Capital.